Ipsen Enters Immuno-Oncology Partnership with Marengo Therapeutics for US$1.6 B
By Swati Sharan
Pharma Deals Review: Vol 2022 Issue 8 (Table of Contents)
Published: 17 Aug-2022
DOI: 10.3833/pdr.v2022.i8.2716 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to broaden its immuno-oncology franchise, Ipsen Pharma has entered into a multi-year collaboration agreement with Marengo Therapeutics to develop and commercialise two precision immuno-oncology compounds leveraging the latter’s Selective T Cell Activation Repertoire (STAR) platform...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS